[The obstetric history of preeclampsia as a further maternal cardiovascular risk factor].

The paper considers the late sequels of preeclampsia that is one of the main causes of poor perinatal outcomes. The idea that this gestational complication shows no noticeable impact on the female health status in the late postpartum periods has long been prevalent. At the same time, recent studies suggest that this cohort of women will have a high cardiovascular risk in future life, which requires the formulation of their management strategy.

[Molecular-genetic determinants of the neoplastic process and state-of-the-art treatment of patients with uterine leiomyoma].

Present-day evidence on uterine leiomyomata has pointed to progesterone and its receptors as a key factor in the mechanisms of auto- and paracrine influences on tumor development and growth. Treatment was determined by a correlation between tumor size and stage of molecular-genetical disorders. A clinico-genealogical study of familial predisposition to uterine leiomyoma, particularly in patients from accumulated disease families contributed to the potential of early detection of tumor and timely effective correction for preservation of reproductive function.

[The effect of n-3 polyunsaturated fatty acids on the lipid spectrum indices in the 2nd-3rd pregnancy trimesters].

The effect of picasol (a preparation of n-3 polyunsaturated fatty acids) on the serum lipid spectrum was studied upon administration of the drug to 60 pregnant women with a high-risk of developing placental insufficiency during II-III trimesters of pregnancy in accordance with a program of randomized placebo controlled double blind trial. In the absence of differences in the level of lipid spectrum parameters prior to picasol administration we found in the III trimester a reliably low content of triglycerides and cholesterol of extremely low density lipoproteids in patients who received picasol.

[Gestational arterial hypertension: clinico-epidemiological study].

Aim: Epidemiological assessment of prevalence of blood hypertension (BH) in pregnant women.

Materials And Methods: Blood pressure and urinary protein were measured in 5160 gravidae observed in female consultations in 4 cities of Russia.

Results: BH was found in 1042(20.

[Adjuvant therapy in uterine myoma].

Many-year studies and clinical experience with steroidal and peptide sexual hormone agonists and antagonists of different generations provides a pathogenetic concept for their use in the treatment of patients with uterine myoma. The impact of adjuvant therapy has been found to be determined by tumor tissue sensitivity to hormonal effects, dosages, therapy duration to a greater extent than the type of a drug from this group. The scope of indications for drug use to suppress the growth of a tumor is limited by its small sizes and its concurrence with benign endometrial hyperplastic processes and/or early internal genital endometriosis.

[Danazol in the treatment of patients with combined pathology of endometrium and myometrium].

Forty-three patients aged 18 to 52 with combined diseases of the uterus and abnormal uterine bleedings were examined and followed up. The patients were prescribed danazon in a dose of 400 mg/day for 6 months to induce a short-term drug pseudomenopause. Immediate (in the cycle of drug discontinuation) and late (6 months after therapy discontinuation) results were assessed.

[The pharmacokinetics and pharmacodynamics of trental in pregnant women with chronic placental insufficiency].

Examining the relationship between the pharmacokinetic characteristics of trental, its effect on platelet aggregation and adverse effects in pregnant females with chronic placental failure has allowed the optimal dosage regimen to be recommended in the third trimester in this abnormality. Its daily dose was found to be 400 mg (100 mg x 4).

[The pharmacokinetics and pharmacodynamics of pentoxifylline (trental) in the third pregnancy trimester].

As a result of studies into the pharmacokinetics of pentoxyfillin, no significant differences were established in the magnitudes of its non-model parameters in normal pregnancy and chronic placental insufficiency. However, there were differences in the metabolite formation rate in the groups under study. Distinctions were detected in the antiaggregation effect of pentoxyfillin.

[Alternative solutions in the treatment of patients with combined benign endometrial and myometrial pathology].

The study included 96 women with combined benign hyperplastic uterine conditions. Half of them underwent a radical uterine resection and were examined at 3.1 +/- 0.

[Rational tactics in the management of pregnancy and labor to prevent perinatal morbidity and mortality].

Results of a cooperative multicenter research have shown that extended studies into scientifically based and regionalized diagnostic screening programmes aimed at sequential follow-up of the gestational phases and early detection of complications is a means to reduce perinatal morbidity and mortality. These programmes should be based on the population characteristics of the fetal and neonatal growth as well as on the incidence and pattern of perinatal disease with consideration of the region-specific birth rates. An adequate range of diagnostic tests provides comprehensive information on intrauterine growth disturbances and allows for finding the criteria for pregnancy prolongation, a complex of intensive therapy steps, and modes of elective delivery together with indications for it.

[The mechanism of the therapeutic effect of norethisterone in hyperplastic diseases of the endo- and myometrium in women of reproductive age].

The paper is concerned with results of a study of clinico-biologic effect of a gestagen norsteroid drug--norcolut--on solitary and combined lesions of the endo- and myometrium. Four hundred and thirty-four patients of reproductive age with hyperplasia or polyps of the endometrium, uterine myoma, internal endometriosis or a combination of the pathologies were examined prior to administration of norcolut and during posttreatment cycle to evaluate the influence of the drug on the female reproductive system. Norcolut exerted the regulatory effect on the rhythm and pattern of menstruation and inhibited tumor growth.